CalciMedica, Inc. (CALC) SEC Filings, Aug 3-21, 2026

CalciMedica, Inc. (CALC) reported that its Chief Business Officer and director, Eric W. Roberts, acquired two warrant awards to purchase common stock. Each warrant covers 186,729 shares of common stock, one with an exercise price of $0.8033 per share expiring on December 25, 2027, and another with an exercise price of $1.00 per share expiring on June 25, 2031. Both warrants are exercisable on or after August 19, 2026 and were issued under a Securities Purchase Agreement dated June 23, 2026, approved by an independent board committee. Each warrant includes a 19.99% ownership cap, limiting exercises that would cause the holder and its affiliates to exceed that percentage of CalciMedica’s outstanding common stock, subject to adjustment with 61 days’ notice.

CalciMedica, Inc. (CALC) reported that its Chief Executive Officer, A. Rachel Leheny, received two warrant grants on August 19, 2026, each for 186,729 warrants to purchase common stock. One warrant has an exercise price of $0.8033 and expires December 25, 2027, with an earlier end date possible 30 days after public disclosure of clearance of the Investigational New Drug Application for CM5480 by the U.S. Food and Drug Administration. The other has an exercise price of $1.00 and expires June 25, 2031. Both warrants are exercisable on or after August 19, 2026 and are subject to a beneficial ownership limitation not to exceed 19.99%. The warrants were acquired from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, approved by an independent committee of the board.

CalciMedica, Inc. (CALC) is the subject of an amended Schedule 13D in which Bering Partners II, L.P., its general partner Bering Partners II GP, L.L.C., and individuals Evgeny Zaytsev and Philip M. Sawyer report beneficial ownership of 3,553,398 shares of common stock in aggregate, representing 9.99% of the class. This stake consists of 2,113,513 common shares plus warrants exercisable within 60 days for an additional 1,439,885 shares, including Common Stock Warrants and Series A and Series B Warrants.

The filing states that stockholder approval for issuing the Series A and Series B Warrants was obtained on August 19, 2026, and these warrants held by Bering II were issued the same day. A 9.99% Beneficial Ownership Limitation in the Series A and B Warrants prevents exercise that would push ownership above this threshold, so further warrant shares (an additional 795,650 from each of Series A and B) are excluded from the reported beneficial ownership. The reporting persons state they have shared voting and dispositive power over the reported shares and have not engaged in other transactions in CalciMedica securities in the past 60 days.

CalciMedica, Inc. (CALC) reported results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing shares of common stock authorized for issuance under the plan by 7,500,000 and revising how the annual automatic share reserve increase is calculated.

Stockholders elected two Class III directors to terms through the 2029 annual meeting, ratified Baker Tilly US, LLP as independent auditor for 2026, and approved, on an advisory basis, executive compensation and an annual say‑on‑pay frequency. They also approved an amendment to the certificate of incorporation to permit a reverse stock split in a range of 1‑for‑2 to 1‑for‑10, with a proportional reduction in authorized common shares, to be implemented at the Board’s discretion.

In addition, stockholders approved, for Nasdaq Listing Rule 5635(d) purposes, the issuance of Series A and Series B common stock warrants and related shares under a June 23, 2026 Securities Purchase Agreement, and, under Rule 5635(c), similar warrant issuances to certain directors and officers.

Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP, reported beneficial ownership of 2,489,729 shares of CalciMedica, Inc. common stock. This represents 8.1% of the company’s outstanding common stock.

Woodline Partners reported sole voting and sole dispositive power30,736,401 shares

Armistice Capital, LLC and Steven Boyd report a significant holding in CalciMedica, Inc. They disclose beneficial ownership of 3,411,361 shares of CalciMedica common stock, representing 9.99% of the class. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported.

The shares are directly held by Armistice Capital Master Fund Ltd., while Armistice Capital serves as investment manager under an Investment Management Agreement and may be deemed to beneficially own the securities. Steven Boyd, as managing member of Armistice Capital, may also be deemed a beneficial owner. The Master Fund has the right to receive dividends and sale proceeds from the reported securities.

CalciMedica, Inc. reported second-quarter 2026 results as a clinical-stage biopharmaceutical company with no product revenue and an accumulated deficit of $192.0 million. For the quarter ended June 30, 2026, operating expenses fell to $4.0 million from $6.6 million a year earlier, reflecting lower research and development and general and administrative spending.

The company recorded a Q2 2026 net loss of $7.7 million compared with $6.0 million in Q2 2025, driven partly by a $3.6 million noncash loss from changes in fair value of financial instruments. For the first six months of 2026, net loss was $2.7 million versus $11.0 million in the prior-year period, largely due to favorable fair value movements earlier in the year.

Cash and cash equivalents increased to $18.6 million at June 30, 2026 from $11.5 million at year-end, primarily from a June PIPE financing and at-the-market sales providing $15.0 million gross proceeds. Total liabilities decreased to $14.0 million, while stockholders’ equity improved from a deficit of $(6.6) million to positive equity of $5.5 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital, given projected operating needs and a $9.2 million fair-valued promissory note and $1.3 million warrant liability on the balance sheet.

CalciMedica, Inc. reported second quarter 2026 results and outlined pipeline and financing updates. A private placement of up to approximately $49 million, including approximately $15 million upfront, is intended to advance its pulmonary hypertension strategy around Auxora and oral candidate CM5480. The company plans a Phase 1b proof‑of‑concept trial of Auxora in pulmonary arterial hypertension with data anticipated in mid‑2027, and expects an IND submission for CM5480 in mid‑2027. In acute pancreatitis, the FDA aligned on the Phase 2b trial design with a primary endpoint focused on reducing new‑onset severe respiratory failure, though trial initiation depends on additional financing. Cash and cash equivalents were $18.6 million as of June 30, 2026, and the company expects its cash to fund operations into the second half of 2027. For the quarter, net loss was $7.7 million (or $0.45 per share), compared with a net loss of $6.0 million (or $0.40 per share) a year earlier, while operating expenses declined due to lower R&D and G&A spending.